The Ebola Outbreak With No Vaccine Has Reached Europe — and It’s Already the Second-Worst on Record

The Democratic Republic of the Congo’s Ministry of Health reported 1,118 confirmed cases of Ebola disease caused by the Bundibugyo virus as of June 24, 2026, including 291 confirmed deaths and 408 patients held in isolation — making this the second-largest Ebola outbreak on record, surpassed only by the 2014–2016 West Africa epidemic. Ituri province accounts for 1,020 of those confirmed cases across 22 health zones, with the outbreak also spreading into North Kivu (95 cases), South Kivu (3 cases), and neighboring Uganda [1, 2].

France confirmed the first imported Ebola case in the EU and European Economic Area on June 24, when a doctor who had traveled to the DRC on a humanitarian mission tested positive upon returning to the country, French health authorities announced. The World Health Organization had declared the outbreak a Public Health Emergency of International Concern on May 17, 2026, citing the speed of transmission, the conflict-zone geography of the epicenter, and the critical absence of any approved vaccine or specific treatment for the Bundibugyo strain — a distinction that sets this crisis apart from prior large outbreaks of the Zaire strain, for which an effective licensed vaccine exists [2, 3].

Why It Sucks:

Congolese Communities and Frontline Health Workers

• No vaccine leaves frontline workers completely unprotected. Unlike the Zaire strain that ravaged West Africa a decade ago, there is no licensed vaccine for the Bundibugyo virus, meaning health workers who must care for infected patients in Ituri and North Kivu lack the primary layer of protection that has been available in more recent outbreaks [1, 2].
• Active conflict zones are the outbreak’s epicenter. Ituri and North Kivu have endured prolonged armed conflict for years; displacement camps, militia activity, and collapsed public health infrastructure make contact tracing and patient isolation nearly impossible in the regions where transmission is most intense [1, 5].
• International funding arrives too slowly to contain spread. Frontline organizations have documented that international financing for Ebola response typically takes weeks to mobilize at scale, and by the time resources reach field operations, outbreak chains have multiplied across health zones that had no baseline infrastructure to begin with [5].

WHO and Global Health Institutions

• A PHEIC declaration hasn’t stopped accelerating case counts. The WHO declared this outbreak a Public Health Emergency of International Concern on May 17, 2026 — yet more than five weeks later the case count exceeds 1,100 and the outbreak has spread across two countries and reached a third continent, raising questions about whether the global response architecture is functioning [1, 3].
• The Bundibugyo vaccine gap is a decades-long failure. Scientists have recognized Bundibugyo virus as a distinct and dangerous Ebola species since its first identified outbreak in 2007, yet no approved vaccine or targeted therapeutic has been developed for it; global research funding has consistently concentrated on the Zaire strain that drove the deadliest previous outbreaks [2, 4].
• Multi-continent spread overwhelms existing coordination frameworks. With confirmed Ebola cases now in the DRC, Uganda, and France, the outbreak spans WHO’s African and European regional offices simultaneously, straining coordination mechanisms that were designed for geographically concentrated emergencies rather than intercontinental containment scenarios [2, 3].

European Governments

• The France case proves this outbreak is not geographically contained. The confirmation of a Bundibugyo case in a returning French doctor — the first case anywhere in the EU and EEA — demonstrates that travel-linked importation is already occurring, placing European health agencies into active surveillance and contact-tracing operations [3].
• European hospitals have no targeted Bundibugyo treatment either. Like frontline health workers in the DRC, European clinicians treating the Paris case must rely on supportive care alone; there is no antiviral, monoclonal antibody therapy, or post-exposure prophylaxis approved for Bundibugyo, leaving hospitals to manage a highly lethal pathogen with isolation protocols as their primary tool [2, 4].
• Travel restrictions create an unresolvable diplomatic dilemma. European governments are under pressure from domestic health agencies to restrict travel to outbreak zones, while simultaneously facing diplomatic pushback against measures that would further isolate an already crisis-stricken DRC; there is no policy option that satisfies both the public health imperative and the humanitarian and geopolitical obligations simultaneously [3, 5].

Sources & Citations:

[1] WHO: Ebola outbreak — DRC 2026
[2] WHO Disease Outbreak News (DON608): Ebola disease caused by Bundibugyo virus, DRC & Uganda
[3] ECDC: Ebola disease outbreak in the Democratic Republic of the Congo and Uganda
[4] CDC: Ebola Outbreak — Current Situation
[5] MSF: Ebola disease outbreak 2026 — how MSF is responding